Liothyronine modified release - Archimedes/T3 Therapeutics

Drug Profile

Liothyronine modified release - Archimedes/T3 Therapeutics

Alternative Names: T3; T3-modified release

Latest Information Update: 12 Sep 2011

Price : $50

At a glance

  • Originator T3 Therapeutics LLC
  • Developer Archimedes Pharma; T3 Therapeutics
  • Class Amino acids; Small molecules; Thyronines
  • Mechanism of Action Thyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Heart failure; Hypothyroidism

Most Recent Events

  • 12 Sep 2011 No development reported - Phase-I for Hypothyroidism in USA (PO)
  • 12 Sep 2011 No development reported - Phase-I for Congestive heart failure in USA (PO)
  • 06 Jun 2008 Phase-I clinical trials in Hypothyroidism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top